학술논문
EE42 Economic Evaluation of Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in Japan
Document Type
Abstract
Author
Source
In Value in Health June 2023 26(6) Supplement:S67-S67
Subject
Language
ISSN
1098-3015